

Brief Communication  
Pediatrics



# COVID-19 Vaccination Status Among Korean Pediatric Population With Comorbidities

Areum Shin ,<sup>1\*</sup> Dong Wook Kim ,<sup>2\*</sup> Young-Eun Kim ,<sup>3</sup> Doo Ri Kim ,<sup>1</sup> Jaehun Jung ,<sup>4,5</sup> and Yae-Jean Kim ,<sup>1,6</sup>

<sup>1</sup>Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

<sup>2</sup>Department of Information and Statistics, Department of Bio & Medical Big Data, Research Institute of Natural Science, Gyeongsang National University, Jinju, Korea

<sup>3</sup>Department of Big Data Strategy, National Health Insurance Service, Wonju, Korea

<sup>4</sup>Department of Preventive Medicine, Gachon University College of Medicine, Incheon, Korea

<sup>5</sup>Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea

<sup>6</sup>Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Seoul, Korea

OPEN ACCESS

**Received:** Mar 14, 2023

**Accepted:** Jun 20, 2023

**Published online:** Jul 26, 2023

**Address for Correspondence:**

**Yae-Jean Kim, MD, PhD**

Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea.

Email: yaejeankim@skku.edu

**Jaehun Jung, MD, PhD**

Department of Preventive Medicine, Gachon University College of Medicine, 38-13 Dokjeom-ro 3-beon-gil, Namdong-gu, Incheon 21565, Republic of Korea.

Email: eastside1st@gmail.com

\*Areum Shin and Dong Wook Kim equally contributed to this study.

© 2023 The Korean Academy of Medical Sciences.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

**ORCID iDs**

Areum Shin

<https://orcid.org/0000-0003-3341-0447>

Dong Wook Kim

<https://orcid.org/0000-0002-4478-3794>

Young-Eun Kim

<https://orcid.org/0000-0003-0694-6844>

Doo Ri Kim

<https://orcid.org/0000-0001-5233-4043>

## ABSTRACT

The pediatric population with comorbidities is a high-risk group for severe coronavirus disease 2019 (COVID-19). As of January 2023, the COVID-19 vaccination rate for at least two doses among Korean children 5–11 years is low at 1.1%. We summarized the COVID-19 vaccination status for the pediatric population (5–17 years) with comorbidities through July 2022 using the National Health Insurance Service database. Pediatric patients with comorbidities had higher vaccination rates than the general pediatric population (2.4% vs. 1.1% in 5–11-year-olds [ $P < 0.001$ ], 76.5% vs. 66.1% in 12–17-year-olds [ $P < 0.001$ ]). However, there were substantial differences according to comorbidity category, and the 2-dose vaccination rate was lowest among children with immunodeficiency in all age groups (1.1% in 5–11-year-olds, 51.2% in 12–17-year-olds). The COVID-19 vaccination rate among Korean children has remained stagnant at a low proportion despite ongoing outreach. Thus, more proactive strategies are needed alongside continuous surveillance.

**Keywords:** COVID-19 Vaccine; Children; Comorbidity

Children have generally experienced a relatively mild clinical manifestation of coronavirus disease 2019 (COVID-19) since the early phase of the pandemic. During delta and omicron variant circulation, the number of pediatric patients with COVID-19 greatly increased; subsequently, severe pediatric cases also increased.<sup>1,2</sup> Severe COVID-19 requires intensive care, ventilator or hemodynamic support, and can result in organ system complications or death.<sup>3</sup> Although the overall infection fatality rate of COVID-19 is low for children, most deaths have been reported in pediatric patients with comorbidities.<sup>4,5</sup>

Several studies have explored the risk factors for severe pediatric COVID-19, and disease categories such as immunocompromised condition, cardiovascular disease, chronic lung disease, neurologic disease, diabetes, and obesity have been reported as pediatric high-risk comorbidities.<sup>6,7</sup> Because immunization with COVID-19 vaccines prevents progression to

Jaehun Jung   
<https://orcid.org/0000-0002-4856-3668>  
 Yae-Jean Kim   
<https://orcid.org/0000-0002-8367-3424>

#### Disclosure

The authors have no potential conflicts of interest to disclose.

#### Author Contributions

Conceptualization: Kim DR, Jung J, Kim YJ.  
 Data curation: Shin A, Kim YE, Kim DR, Jung J, Kim YJ. Formal analysis: Shin A, Kim DW, Kim YE, Jung J. Investigation: Shin A, Kim DW, Kim YE. Methodology: Kim DW, Kim YE, Kim DR, Jung J. Resources: Kim YE. Supervision: Kim YJ. Validation: Kim DW, Kim YE, Jung J. Writing - original draft: Shin A, Kim DW. Writing - review & editing: Kim YE, Kim DR, Kim YJ.

severe disease, children with high-risk comorbidities are a priority for COVID-19 vaccination in many countries, including Korea.

The Korea Disease Control and Prevention Agency (KDCA) recommended COVID-19 vaccination in pediatric patients with high-risk diseases including chronic lung disease, chronic heart disease, chronic liver disease, chronic kidney disease, neuro-muscular disease, diabetes mellitus, obesity, and immunocompromised condition.<sup>8</sup> KDCA recommended vaccination for all 12–17-year-old adolescents in mid-October 2021, while for high-risk 5–11-year-olds in late March 2022 at the middle of Omicron surge. Vaccination in healthy children of 5–11 years was left to parental choice. Third-shot and bivalent vaccine were recommended to high-risk 12–17-year-olds in mid-March 2022 and December 2022, respectively.

COVID-19 vaccination policies for children 5–11 years were differed by country, which were compared among four countries (United States, United Kingdom, Japan, and Korea) along with national vaccination rates in **Supplementary Table 1**. The vaccination was implemented about one month before the omicron predominance in the US (early November 2021), one month after omicron in the UK (end of January 2022), and two months after omicron in Japan (end of February 2022) and Korea (end of March 2022). It was recommended in all children 5–11 years in the US, while it was recommended in high-risk group in the UK, Japan, and Korea. Of note, Japan expanded the recommendation to all children after six months, concerning for the low vaccination rate of 18.5% at the time.<sup>9</sup> As a result, in Korea, the two-dose vaccination rate for 5–11-year-olds remained at the lowest 1.1% as of January 2023 despite 10 months of implementation, compared to 19.1% in Japan after 11 months and 29.7% in the U.S. after 10 months.<sup>10–12</sup> Meanwhile, among the US pediatric population, Asian children had the highest vaccination rate: 57.1% compared with 29.0% of white children.<sup>12</sup>

In this study, we summarized overall COVID-19 vaccination status as of July 2022, in the Korean pediatric population (5–17 years) with comorbidities in addition to high-risk diseases for whom KDCA recommended COVID-19 vaccination and compared it to that of the general population in the same age group using the National Health Insurance Service database.

For comorbidity classification, a list of International Classification of Diseases and Related Health Problems, 10th Edition codes for systemic chronic diseases was created (**Supplementary Table 2**). Diseases with a known risk for severe COVID-19 were included, and acute infection codes were excluded. Accordingly, 12 organ-specific comorbidity categories encompassing 45 individual diseases were identified.

Pediatric patients with chronic disease who had a history of at least three outpatient clinic visits or at least one hospitalization were identified from April 2021 to March 2022. Vaccination history in the patient population aged 5–17 years through July 2022 was analyzed. The population was divided into two groups: a 5–11 years age group and a 12–17 years age group. Vaccination rate data for the total pediatric populations of both age groups as of July 28, 2022, were collected from a KDCA press release.<sup>13</sup> For statistical analysis, binomial distribution was used to evaluate whether significant difference in vaccination rate exists between the specific diseases or comorbidity categories with total population.

A total of 246,593 children was identified with comorbidities, which accounted for 4.2% of the total pediatric population (N = 5,836,542) in the 5–17-year age group in Korea. Detailed data on the proportions of comorbidity categories in each age group are summarized in **Table 1**.

**Table 1.** COVID-19 vaccination rates among the pediatric population with comorbidities as of July 31, 2022

Comorbidity category	Younger group (5–11 years)				Older group (12–17 years)				
	Total No. <sup>b</sup> (people)	Proportions, <sup>c</sup> %	One-dose, %	Two- doses, %	Total No. (people)	Proportions, %	One-dose, %	Two- doses, %	Three- doses, %
Total pediatric population <sup>a</sup>	3,067,614		1.6	1.1	2,768,928		68.7	66.1	10.5
Pediatric population with comorbidities	134,011	4.4	3.3	2.4	112,582	4.1	79.1	76.5	21.7
Neoplasm	3,105	2.3	2.4	1.7	3,396	3.0	54.7	52.1	10.7
Solid tumor	1,375	44.3	3.2	2.4	1,676	49.4	61.3	58.7	12.1
Hematologic malignancy	1,730	55.7	1.7	1.2	1,720	50.6	48.1	45.8	9.3
Blood disorder	6,001	4.5	2.5	1.7	11,010	9.8	82.0	79.4	19.7
Anemia	2,917	48.6	2.9	2.1	9,056	82.3	86.1	83.7	21.3
Coagulation defect	2,718	45.3	2.1	1.4	1,622	14.7	63.6	60.1	11.6
Granulocyte defect	350	5.8	2.6	1.7	298	2.7	58.1	55.7	13.4
Diseases of the spleen	16	0.3	0.0	0.0	34	0.3	82.4	76.5	23.5
Immunodeficiency	265	0.2	1.5	1.1	389	0.4	54.0	51.2	10.0
Primary immunodeficiency	263	99.2	1.5	1.1	382	98.2	53.7	50.8	9.4
HIV infection	2	0.8	0.0	0.0	7	1.8	71.4	71.4	42.9
Endocrinologic and metabolic disorders	9,473	7.1	4.0	2.9	16,583	14.7	82.5	80.2	22.4
Disorders of the thyroid gland	6,040	63.8	3.0	2.3	8,389	50.6	81.2	78.7	17.5
Diabetes mellitus	1,184	12.5	8.0	5.5	5,254	31.7	85.7	83.8	30.9
Inborn errors of metabolism	2,249	23.7	4.6	3.1	2,940	17.7	80.4	78.4	21.2
Obesity	1,162	0.9	5.4	4.6	912	0.8	83.4	81.1	23.1
Diseases of the nervous system	33,932	25.3	3.8	2.8	23,151	20.6	68.5	65.8	19.2
Congenital malformation of the nervous system	1,286	3.8	4.7	3.2	589	2.5	69.3	66.6	14.9
Epilepsy	10,765	31.7	3.5	2.6	10,531	45.5	68.2	65.2	17.1
Encephalitis, myelitis, and encephalomyelitis	349	1.0	1.7	1.7	173	0.7	59.0	53.8	11.0
Systemic atrophies	173	0.5	3.5	2.9	170	0.7	58.2	56.5	18.2
Demyelinating disease	61	0.2	1.6	0.0	120	0.5	55.0	50.8	11.7
Diseases of the myoneural junction and muscle	756	2.2	4.5	3.2	784	3.4	56.3	53.6	16.7
Cerebral palsy	3,509	10.3	4.4	3.5	2,147	9.3	62.6	60.4	17.4
Mental retardation	4,189	12.3	6.5	4.8	4,071	17.6	78.6	76.4	29.8
Developmental delay	12,954	38.2	3.0	2.2	4,566	19.7	66.4	63.6	17.1
Diseases of the circulatory system	6,332	4.7	2.7	1.9	5,799	5.2	73.0	69.4	17.5
Congenital malformations of the circulatory system	4,847	76.6	2.8	2.0	2,823	48.7	68.6	65.3	14.7
Cardiomyopathy	206	3.3	2.4	1.9	209	3.6	64.6	60.3	13.4
Conduction disorders	854	13.5	1.4	1.1	1,294	22.3	73.3	69.4	16.9
Pulmonary heart diseases	68	1.1	8.8	4.4	63	1.1	47.6	44.4	9.5
Heart failure	50	0.8	4.0	2.0	137	2.4	76.6	66.4	11.7
HTN	251	4.0	4.4	3.2	1,244	21.5	85.2	81.8	25.9
Coronary artery aneurysm	56	0.9	3.6	3.6	29	0.5	58.6	58.6	17.2
Diseases of the respiratory system	43,819	32.7	2.6	1.9	12,453	11.1	80.7	78.0	19.8
Congenital malformations of the respiratory system	363	0.8	2.8	2.2	58	0.5	69.0	67.2	15.5
Bronchiectasis	22	0.0	9.1	4.5	38	0.3	63.2	57.9	28.9
Bronchiolitis obliterans	211	0.5	4.7	3.8	95	0.8	64.2	62.1	11.6
Bronchopulmonary dysplasia	64	0.1	9.4	6.3	2	0.0	0.0	0.0	0.0
Respiratory failure	100	0.2	6.0	6.0	70	0.6	31.4	28.6	12.9
Asthma	42,059	96.0	2.6	1.9	11,254	90.4	81.0	78.2	20.0
Obstructive sleep apnea	1,000	2.3	3.8	2.7	936	7.5	83.9	81.8	18.5
Diseases of the digestive system	19,441	14.5	4.0	2.9	27,756	24.7	87.8	85.4	28.2
Congenital malformations of the digestive system	2,527	13.0	2.0	1.2	636	2.3	77.2	73.9	18.4
Inflammatory bowel disease	13,497	69.4	3.6	2.6	19,120	68.9	88.5	86.1	29.3
Intestinal malabsorption	19	0.0	0.0	0.0	22	0.0	81.8	81.8	22.7
Diseases of the liver	3,398	17.5	7.5	5.2	7,978	28.7	86.8	84.7	26.5
Diseases of the musculoskeletal system and connective tissue	2,489	1.9	2.2	1.6	5,315	4.7	82.8	80.0	20.5
Juvenile idiopathic arthritis	416	16.7	3.8	2.9	875	16.5	73.4	69.9	16.2
Systemic connective tissue disorders	1,660	66.7	1.7	1.3	927	17.4	66.0	63.1	12.9
Spondylopathies	413	16.6	2.7	1.7	3,513	66.1	89.6	87.0	23.5

(continued to the next page)

**Table 1.** (Continued) COVID-19 vaccination rates among the pediatric population with comorbidities as of July 31, 2022

Comorbidity category	Younger group (5–11 years)				Older group (12–17 years)				
	Total No. <sup>b</sup> (people)	Proportions, <sup>c</sup> %	One-dose, %	Two- doses, %	Total No. (people)	Proportions, %	One-dose, %	Two- doses, %	Three- doses, %
Diseases of the genitourinary system	6,202	4.6	3.9	2.6	4,193	3.3	77.8	75.0	17.8
Congenital malformations of the urinary system	1,147	18.5	2.7	1.7	443	10.6	77.4	75.2	14.9
Glomerular disease	1,679	27.1	3.6	2.4	1,700	40.5	73.9	70.7	14.5
Tubulointerstitial disease	3,162	51.0	2.5	1.8	1,728	41.2	84.1	81.7	21.8
Chronic kidney disease	214	3.5	6.1	2.8	322	7.7	65.2	60.9	17.7
Congenital malformations, deformations, and chromosomal abnormalities	1,790	1.3	2.5	1.5	1,625	1.4	81.7	79.0	19.3

COVID-19 = coronavirus disease 2019, HIV = human immunodeficiency virus, HTN = hypertension.

<sup>a</sup>2022.07.28 Korea Disease Control and Prevention Agency.

<sup>b</sup>Number of pediatric patients according to comorbidity category or individual disease.


<sup>c</sup>Proportions of comorbidity categories were estimated among the total age-specific pediatric population with comorbidities, while proportions of individual diseases were calculated through the corresponding comorbidity category.


Overall vaccination rates among the pediatric population with comorbidities appeared to be higher than those of the general pediatric population regardless of age group and number of doses received (**Fig. 1**). Among the total 5–17-year-olds, two-dose vaccination rates were 36.2% in children with comorbidities and 32.0% in the general pediatric population. In the 5–11 years age group, 1.1% of all children and 2.4% of children with comorbidities received at least two vaccine doses ( $P < 0.001$ ). In the 12–17 years age group, 66.1% of all adolescents and 76.5% of adolescents with comorbidities received at least two COVID-19 vaccine doses ( $P < 0.001$ ). Of note, the third-dose vaccination rate for the 12–17 years age group was two times higher in the comorbidity group (21.7%) than in the general pediatric population (10.5%) ( $P < 0.001$ ). We organized comorbidity categories in descending order of two-dose vaccination rate for each age group (**Fig. 1**). Pediatric patients with gastrointestinal disorders, obesity, and endocrinologic disorders showed the highest vaccination rates, while patients with immunodeficiency had the lowest vaccination rates in both age groups. For 12–17-year-olds, both immunodeficiency group (51.2% vs. 66.1%,  $P < 0.001$ ) and neoplasm group (51.2% vs. 66.1%,  $P < 0.001$ ) showed lower two-dose vaccination rate than the general population with a statistical difference.

Vaccination rates at the individual disease level were further analyzed (**Fig. 2**). Interestingly, respiratory diseases such as bronchopulmonary dysplasia in the 5–11-year-old group (two-dose), obstructive sleep apnea in the 12–17-year-old group (two-dose), and bronchiectasis in the 12–17-year-old group (three-dose) ranked high. Similarly, the lowest vaccination tendency was found among children with primary immunodeficiencies or hematologic malignancies. For 12–17-year-olds, primary immunodeficiency (50.8% vs. 66.1%,  $P < 0.001$ ) and hematologic malignancy (45.8% vs. 66.1%,  $P < 0.001$ ) showed a lower two-dose vaccination rate than the general population with a statistical difference.

In summary, despite the overall low COVID-19 vaccination rate among Korean children, the vaccination rate of children with comorbidities was higher than that of the general pediatric population. However, there was a substantial difference as large as 30% in the rate among comorbidity categories. Children with immunodeficiencies or hematologic malignancies, who are high-risk for severe COVID-19, had the lowest vaccination rate.<sup>14</sup>

Pediatric COVID-19 vaccine hesitancy, a delay in acceptance of vaccines despite availability, has become a global phenomenon. A recent study found that parents who are hesitant toward general childhood vaccines are more likely to be hesitant toward the COVID-19





**Fig. 2.** Differential tendency of COVID-19 vaccination rates for individual diseases including high-risk disorders. **(A)** Two-dose vaccination rates in 5–11 years. **(B)** Two-dose vaccination rates in 12–17 years. **(C)** Three-dose vaccination rates in 12–17 years. COVID-19 = coronavirus disease 2019. <sup>a</sup>There are significant differences between the maximum values of the graphs (100% vs. 100% vs. 50%). <sup>b</sup>Bronchopulmonary dysplasia was included for the 5–11-year-olds but was excluded for the 12–17-year-olds considering the disease epidemiology. In the same context, systemic connective tissue disorders were included in the 12–17-year-olds but were excluded for the 5–11-year-olds. <sup>c</sup>This indicates a significant difference between vaccination rates of patients with each individual disease compared to that of total pediatric population in age groups via binomial distribution ( $P < 0.001$ ).



vaccine.<sup>15</sup> In Korea, even considering the difference in the level of recommendation, the low COVID-19 vaccination rate in children 5–11-year-olds is in sharp contrast to the traditionally high acceptance rate for National Immunization Program (NIP), although comparing the vaccination rates between the COVID-19 vaccine (recommended for high-risk children) and the NIP vaccine (recommended for all children) may not be fair.<sup>16,17</sup>

Since the COVID-19 vaccination in children 5–11 years is recommended only in high-risk group and remained a choice among most healthy children in Korea, whether to get COVID-19 vaccination largely depends on their parents' autonomy. Therefore, parental value judgement weighing the pros and cons of the pediatric vaccination for COVID-19 ever became more important and it appeared to be skewed to conclude not getting a vaccination for their final decision among most Korean parents. One explanation might be the 'infodemic' of common digital rumors which cause misunderstanding to parents to defer COVID-19 vaccination of children.<sup>18–20</sup>

In this context, consistent and proactive recommendations from pediatricians are crucial to promote parental motivation toward pediatric COVID-19 vaccination. For instance, pediatricians who encounter immunocompromised children in their clinics should offer proactive vaccinations and recommendations.<sup>14,21</sup> Additionally, customized consultation to address individual concerns about COVID-19 vaccination from the family of high-risk children would be ideal. However, considering the reality of the limited time pediatricians have at a busy clinic, a simple scale assessing the influence of comorbidity on COVID-19 vaccine acceptance can be introduced as a point-of-care tool for targeted counseling.<sup>22</sup> Currently, COVID-19 vaccination in children 5–17 years old is only provided at primary care facilities, while most children with comorbidities within this age group are followed up at tertiary care centers that do not provide COVID-19 vaccines as part of their routine health care services.

Beginning in February 2023, COVID-19 vaccination for children 6 months and older has been implemented in Korea. Unlike prior implementations, COVID-19 vaccination service was provided at tertiary hospitals as well as primary clinics, which may be helpful to overcome the current COVID-19 vaccine hesitancy for the Korean pediatric population with comorbidities.

Meanwhile, the cumulative number of COVID-19 patients aged 0–19 years in Korea was 6,876,624 as of February 19th, 2023, representing 83.7% of the population in this age group.<sup>23</sup> Thus, the majority of the pediatric population acquired immunity against COVID-19 through natural infection rather than vaccination, as reflected by their high severe acute respiratory syndrome coronavirus 2 nucleocapsid protein seropositivity rate compared with other age groups (5–9 years [90.0%] vs. total [70.0%]) as of January 2023.<sup>24</sup> However, as immunity wanes over time, pediatricians should remain alert to the importance of continuous vaccination of high-risk children including immunocompromised children, even in the post-pandemic era.

This study has several limitations. First, since the disease codes used for data collection were not validated systematically, this could be the limitation to estimate the individual vaccination rates comprehensively. In addition, patients with multiple underlying diseases were accounted for the single main diagnosis. Second, we could only define the high-risk group according to underlying disease categories, although recent studies suggest that COVID-19 risk assignment should be stratified according to disease severity and treatment status.<sup>25</sup> Third, patients receiving immunosuppressive drugs for systemic conditions such as organ-transplant status could not be accounted for separately in the study.

In conclusion, COVID-19 vaccination rates among pediatric population with comorbidities were low, especially in the younger age group (5–11 years). Rates also differed substantially according to underlying disease and were particularly low among children with immunocompromised conditions in all age groups (5–17 years). Because the COVID-19 vaccination rate among Korean children with high-risk disorders is stagnant within a significantly low range despite continuing implementation efforts, more proactive strategies are needed with continuous surveillance.

## Ethics statement

This study was approved by the Institutional Review Board of the Gil Medical Center (GCIRB2023-113). Participant consent was waived by the ethics committee because the data involved routinely collected medical data that was processed anonymously at all stages. The study methods were carried out based on the Declaration of Helsinki.

## ACKNOWLEDGMENTS

This study used the databases of the Korea Disease Control and Prevention Agency and the National Health Insurance Service of Korea for policy and academic research. The research number of this study is KDCA-NHIS-2022-1-448.

## SUPPLEMENTARY MATERIALS

### Supplementary Table 1

Global COVID-19 vaccination policies for children 5–11 years with their outcome

[Click here to view](#)

### Supplementary Table 2

ICD-10 codes for comorbidity category

[Click here to view](#)

## REFERENCES

1. Shi DS, Whitaker M, Marks KJ, Anglin O, Milucky J, Patel K, et al. Hospitalizations of children aged 5-11 years with laboratory-confirmed COVID-19 - COVID-NET, 14 states, March 2020-February 2022. *MMWR Morb Mortal Wkly Rep* 2022;71(16):574-81.  
[PUBMED](#) | [CROSSREF](#)
2. Choi SH, Choi JH, Lee JK, Eun BW, Song SH, Ahn B, et al. Clinical characteristics and outcomes of children with SARS-CoV-2 infection during the delta and omicron variant-dominant periods in Korea. *J Korean Med Sci* 2023;38(9):e65.  
[PUBMED](#) | [CROSSREF](#)
3. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis* 2020;20(8):e192-7.  
[PUBMED](#) | [CROSSREF](#)



4. Bertran M, Amin-Chowdhury Z, Davies HG, Allen H, Clare T, Davison C, et al. COVID-19 deaths in children and young people in England, March 2020 to December 2021: an active prospective national surveillance study. *PLoS Med* 2022;19(11):e1004118.  
[PUBMED](#) | [CROSSREF](#)
5. Shin E, Choe YJ, Ryu B, Kim NY, Lee HJ, Kim DH, et al. Pediatric deaths associated with coronavirus disease 2019 (COVID-19) in Korea. *J Korean Med Sci* 2023;38(3):e21.  
[PUBMED](#) | [CROSSREF](#)
6. Choi YY, Choi SH, Choi JH, Kim DH, Lee JK, Eun BW, et al. SARS-CoV-2-naïve Korean children and adolescents hospitalized with COVID-19 in 2021. *J Korean Med Sci* 2022;37(42):e303.  
[PUBMED](#) | [CROSSREF](#)
7. Woodruff RC, Campbell AP, Taylor CA, Chai SJ, Kawasaki B, Meek J, et al. Risk factors for severe COVID-19 in children. *Pediatrics* 2022;149(1):e2021053418.  
[PUBMED](#) | [CROSSREF](#)
8. Korea Disease Control and Prevention Agency. COVID-19 vaccination for children (March 14, 2022). [https://ncov.kdca.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=6475&contSeq=6475&board\\_id=312&gubun=BDJ](https://ncov.kdca.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=6475&contSeq=6475&board_id=312&gubun=BDJ). Updated 2023. Accessed May 22, 2023.
9. Yomiuri Shimbun. Push to have children ages 5-11 get COVID-19 vaccines gains steam (August 16, 2022). <https://japannews.yomiuri.co.jp/society/coronavirus/20220816-51598/>. Updated 2023. Accessed May 20, 2023.
10. Prime Minister's Office of Japan. COVID-19 vaccination rates by age group (January 7, 2023). <https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html>. Accessed January 7, 2023.
11. Korea Disease Control and Prevention Agency. COVID-19 vaccination rates by age group (January 7, 2023). <https://ncv.kdca.go.kr/allAgerateStatus.es?mid=a11718000000>. Updated 2023. Accessed January 7, 2023.
12. Valier MR, Elam-Evans LD, Mu Y, Santibanez TA, Yankey D, Zhou T, et al. Racial and ethnic differences in COVID-19 vaccination coverage among children and adolescents aged 5-17 years and parental intent to vaccinate their children - National Immunization Survey-Child COVID Module, United States, December 2020-September 2022. *MMWR Morb Mortal Wkly Rep* 2023;72(1):1-8.  
[PUBMED](#) | [CROSSREF](#)
13. Korea Disease Control and Prevention Agency. COVID-19 domestic outbreak and vaccination status (July 28, 2022). [https://ncov.kdca.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=6783&contSeq=6783&board\\_id=312&gubun=ALL](https://ncov.kdca.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=6783&contSeq=6783&board_id=312&gubun=ALL). Updated 2022. Accessed February 10, 2023.
14. Singson JRC, Kirley PD, Pham H, Rothrock G, Armistead I, Meek J, et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 - COVID-NET, 10 states, March 2020-February 2022. *MMWR Morb Mortal Wkly Rep* 2022;71(27):878-84.  
[PUBMED](#) | [CROSSREF](#)
15. Wang CS, Doma R, Westbrook AL, Johnson J, Anderson EJ, Greenbaum LA, et al. Vaccine attitudes and COVID-19 vaccine intention among parents of children with kidney disease or primary hypertension. *Am J Kidney Dis* 2023;81(1):25-35.e1.  
[PUBMED](#) | [CROSSREF](#)
16. Yu JH, Jeong HJ, Kim SJ, Lee JY, Choe YJ, Choi EH, et al. Sustained vaccination coverage during the coronavirus disease 2019 epidemic in the Republic of Korea. *Vaccines (Basel)* 2020;9(1):2.  
[PUBMED](#) | [CROSSREF](#)
17. Korea Disease Control and Prevention Agency. High rate of National Immunization Program for Korean children even during the COVID-19 pandemic (July 28, 2022). <https://www.korea.kr/news/pressReleaseView.do?newsId=156518666>. Updated 2022. Accessed February 10, 2023.
18. Wiegand M, Eagan RL, Karimov R, Lin L, Larson HJ, de Figueiredo A, et al. Global declines in vaccine confidence from 2015 to 2022: a large-scale retrospective analysis. *SSRN*. Forthcoming 2023. DOI: <https://doi.org/10.2139/ssrn.4438003>.  
[CROSSREF](#)
19. Lee M, Seo S, Choi S, Park JH, Kim S, Choe YJ, et al. Parental acceptance of COVID-19 vaccination for children and its association with information sufficiency and credibility in South Korea. *JAMA Netw Open* 2022;5(12):e2246624.  
[PUBMED](#) | [CROSSREF](#)
20. Choi SH, Jo YH, Jo KJ, Park SE. Pediatric and parents' attitudes towards COVID-19 vaccines and intention to vaccinate for children. *J Korean Med Sci* 2021;36(31):e227.  
[PUBMED](#) | [CROSSREF](#)
21. Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. *Lancet Oncol* 2021;22(6):765-78.  
[PUBMED](#) | [CROSSREF](#)

22. Day D, Grech L, Nguyen M, Bain N, Kwok A, Harris S, et al. Serious underlying medical conditions and COVID-19 vaccine hesitancy: a large cross-sectional analysis from Australia. *Vaccines (Basel)* 2022;10(6):851.  
[PUBMED](#) | [CROSSREF](#)
23. Korea Disease Control and Prevention Agency. COVID-19 domestic outbreak and vaccination status (February 19, 2023). [https://ncov.kdca.go.kr/bdBoardList\\_Real.do?brdId=1&brdGubun=11&ncvContSeq=&contSeq=&board\\_id=&gubun=](https://ncov.kdca.go.kr/bdBoardList_Real.do?brdId=1&brdGubun=11&ncvContSeq=&contSeq=&board_id=&gubun=). Updated 2023. Accessed February 19, 2023.
24. Korea Disease Control and Prevention Agency. Nationwide sample survey of COVID-19 seroprevalence, 2nd. [https://www.kdca.go.kr/board/board.do?mid=a20501010000&bid=0015&act=view&list\\_no=721678](https://www.kdca.go.kr/board/board.do?mid=a20501010000&bid=0015&act=view&list_no=721678). Updated 2023. Accessed February 19, 2023.  
[PUBMED](#) | [CROSSREF](#)
25. Farrar DS, Drouin O, Moore Hepburn C, Baerg K, Chan K, Cyr C, et al. Risk factors for severe COVID-19 in hospitalized children in Canada: a national prospective study from March 2020-May 2021. *Lancet Reg Health Am* 2022;15:100337.  
[PUBMED](#) | [CROSSREF](#)